scholarly journals Mycobacterium chimaera as An Underestimated Cause of NTM Lung Diseases in Patients Hospitalized in Pulmonary Wards

2021 ◽  
Vol 70 (3) ◽  
pp. 315-320
Author(s):  
ANNA T. ZABOST ◽  
MONIKA SZTURMOWICZ ◽  
SYLWIA A. BRZEZIŃSKA ◽  
MAGDALENA D. KLATT ◽  
EWA M. AUGUSTYNOWICZ-KOPEĆ
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Lung Diseases ◽  
Mycobacterium Avium Complex ◽  
Interstitial Lung Diseases ◽  
Growth Characteristics ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Mycobacterium Intracellulare ◽  
Species Analysis ◽  
Respiratory Specimens

Mycobacterium chimaera is the newly described species belonging to Mycobacterium avium complex (MAC), with morphology and growth characteristics closely related to Mycobacterium intracellulare. The aim of this retrospective study was to analyze the frequency and clinical significance of M. chimaera identification in the population of patients with previous positive respiratory cultures for M. intracellulare or MAC. 200 strains of M. intracellulare or MAC, isolated from respiratory specimens of patients hospitalized in pulmonary wards, between 2011 and 2020, were retrospectively analyzed with GenoType NTM-DR test. 88 (44%) of strains were re-classified to M. chimaera species. Analysis of clinical data in 30 patients with positive M. chimaera isolates revealed that they were diagnosed with chronic obstructive pulmonary disease (COPD) – 27%, past tuberculosis – 20%, or interstitial lung diseases – 17%, respectively. Non-tuberculous mycobacterial lung disease (NTMLD) caused by M. chimaera has been recognized in 53% of patients, most often in those presenting with post-tuberculous lung lesions. M. chimaera was almost exclusively isolated from respiratory specimens of patients with underlying lung diseases, especially those with COPD and/or past tuberculosis. NTMLD due to M. chimaera was diagnosed predominantly in patients with past tuberculosis.

scholarly journals Smoking and interstitial lung diseases

2015 ◽  
Vol 24 (137) ◽  
pp. 428-435 ◽  
Author(s):  
George A. Margaritopoulos ◽  
Eirini Vasarmidi ◽  
Joseph Jacob ◽  
Athol U. Wells ◽  
Katerina M. Antoniou
Keyword(s):  
Lung Cancer ◽  
Chronic Obstructive Pulmonary Disease ◽  
Langerhans Cell Histiocytosis ◽  
Lung Diseases ◽  
Interstitial Lung Diseases ◽  
Lung Damage ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Pulmonary Langerhans Cell Histiocytosis

For many years has been well known that smoking could cause lung damage. Chronic obstructive pulmonary disease and lung cancer have been the two most common smoking-related lung diseases. In the recent years, attention has also focused on the role of smoking in the development of interstitial lung diseases (ILDs). Indeed, there are three diseases, namely respiratory bronchiolitis-associated ILD, desquamative interstitial pneumonia and pulmonary Langerhans cell histiocytosis, that are currently considered aetiologically linked to smoking and a few others which are more likely to develop in smokers. Here, we aim to focus on the most recent findings regarding the role of smoking in the pathogenesis and clinical behaviour of ILDs.

scholarly journals Azithromycin in Coronavirus Disease-19: What We Know?

2020 ◽  
Vol 8 (T1) ◽  
pp. 92-96
Author(s):  
Ashok Agrawal
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Lung Diseases ◽  
Viral Infections ◽  
Interstitial Lung Diseases ◽  
Chronic Obstructive ◽  
Broad Spectrum Antibiotic ◽  
Obstructive Pulmonary Disease ◽  
Chronic Lung Diseases ◽  
Immunomodulatory Properties ◽  
Novel Coronavirus

Azithromycin (AZM) is a broad-spectrum antibiotic with anti-inflammatory and immunomodulatory properties. It is particularly used in chronic lung diseases including chronic obstructive pulmonary disease, asthma, interstitial lung diseases, bronchiectasis, and cystic fibrosis. AZM has not approved for the treatment of viral infections, but some study supported its antiviral activity. Recently, few studies are emphasized used AZM in combination with chloroquine/hydroxychloroquine for the treatment of novel coronavirus disease-2019 (COVID-19). The present review highlighted uses, dosage, and adverse effects of AZM in COVID-19 based on available literature.

scholarly journals Chronic Obstructive Pulmonary Disease: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases

2014 ◽  
Vol 11 (Supplement 3) ◽  
pp. S154-S160 ◽  
Author(s):  
M. Bradley Drummond ◽  
A. Sonia Buist ◽  
James D. Crapo ◽  
Robert A. Wise ◽  
Stephen I. Rennard
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Primary Prevention ◽  
Pulmonary Disease ◽  
Lung Diseases ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Chronic Lung Diseases

The state of the cardiovascular system in occupational bronchitis and chronic obstructive pulmonary disease, not associated with the impact of harmful industrial factors

2021 ◽  
pp. 55-68
Author(s):  
Vyacheslav S. Lotkov ◽  
Anton Vladimirovich Glazistov ◽  
Antonina G. Baykova ◽  
Marina Yuryevna Vostroknutova ◽  
Natalia E. Lavrentieva
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Cardiovascular System ◽  
Pulmonary Disease ◽  
Lung Diseases ◽  
Chronic Obstructive ◽  
External Respiration ◽  
Obstructive Pulmonary Disease ◽  
Occupational Lung Diseases ◽  
The Right ◽  
The Impact

The formation and progression of chronic dust bronchitis and chronic bronchitis of toxic-chemical etiology, chronic obstructive pulmonary disease is accompanied by an increase in the degree of ventilation disorders, echocardiographic signs of hypertrophy and dilatation of the right ventricle are formed, typical for chronic pulmonary heart disease. The progression of disturbances in the function of external respiration in dusty lung diseases leads to a decrease in myocardial contractility. The detection of hemodynamic disturbances at the early stages of the development of occupational lung diseases indicates the need for individual monitoring of the functional state of the cardiovascular system in the process of contact with industrial aerosols, especially in groups of workers with long-term exposure.

scholarly journals Roles of Mesenchymal Cells in the Lung: From Lung Development to Chronic Obstructive Pulmonary Disease

Cells ◽  
2021 ◽  
Vol 10 (12) ◽  
pp. 3467
Author(s):  
Amel Nasri ◽  
Florent Foisset ◽  
Engi Ahmed ◽  
Zakaria Lahmar ◽  
Isabelle Vachier ◽  
...  
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Lung Development ◽  
Lung Diseases ◽  
Mesenchymal Cells ◽  
Chronic Obstructive ◽  
Multilineage Differentiation ◽  
Cell Type ◽  
Obstructive Pulmonary Disease ◽  
Lung Regeneration

Mesenchymal cells are an essential cell type because of their role in tissue support, their multilineage differentiation capacities and their potential clinical applications. They play a crucial role during lung development by interacting with airway epithelium, and also during lung regeneration and remodeling after injury. However, much less is known about their function in lung disease. In this review, we discuss the origins of mesenchymal cells during lung development, their crosstalk with the epithelium, and their role in lung diseases, particularly in chronic obstructive pulmonary disease.

Sign in / Sign up

Export Citation Format

Share Document